research_funding

Barnard, Vt. – September 13, 2026 -- MIB Agents began accepting letters of intent on September 9 for its 2027 OutSmarting Osteosarcoma research grant cycle, offering a combined $150,000 to fund translational studies on the pediatric bone cancer.

Two grants totaling $150,000 target established and emerging researchers

The 2027 cycle includes a $100,000 Hero Grant and a $50,000 Hope Young Investigator Grant. Since launching in 2017, the program has distributed more than $2.9 million across 37 investigators studying osteosarcoma, an aggressive primary bone cancer diagnosed in roughly 1,000 people annually in the United States, nearly half of them children, adolescents and young adults.

Los Angeles – September 13, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS), pushing the company's total non-dilutive federal funding past $8 million.

Tenth SBIR grant matches private capital raised to date

The award, Partillion's 10th SBIR grant, was competitively secured through NIH's Direct-to-Phase II mechanism and roughly matches the company's private investment total, with no additional equity exchanged. The funding, awarded under grant number R44GM165220, will support development of the company's Cell-Cell-seq workflows over two years.

Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Board addition brings direct experience from an FDA-cleared Alzheimer's drug

Ronald B. DeMattos spent more than 20 years in neuroscience discovery at Eli Lilly, most recently as Senior Vice President and Chief Scientific Officer for Neurobiologics, where he led development of candidates that advanced to clinical studies including donanemab, the FDA-cleared amyloid-lowering antibody marketed as Kisunla for early Alzheimer's disease.

NEW HAVEN, Conn. -- Aug. 31, 2026 -- Yale School of Medicine has secured a nearly $25 million grant from the Aligning Research to Impact Autism (ARIA) initiative to build the first high-resolution map of the developing human brain and pinpoint where autism diverges from typical neural development.

The award, part of ARIA's Human Developmental Neurobiology Research Hub, funds two Yale-led projects within a four-project collaboration that also involves Harvard University. Combined, the initiative targets a gap researchers say has stalled autism drug and diagnostic development for decades: no detailed reference map exists for how the human brain wires itself in the first years of life.